Iter-4360dd15-0134-transcript
第 134 轮执行轨迹
→ call search_memory({"limit":10,"query":"4360dd15 NEXT_FOCUS PMC4713958 PMID 22149876 erratum abstract original source"})【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0094-transcript", "tags": "iteration transcript", "modified": "20260424210844000", "preview": "!! 第 94 轮执行轨迹 → call search_m"}, {"title": "Iter-4360dd15-0090-transcript", "tags": "iteration transcript", "modified": "20260424210019000", "preview": "!! 第 90 轮执行轨迹 → call search_memory({"limit":10,"query":"4360dd15 BOLERO-2 erratum corrected abstract sentence PMID PMCID DOI"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0133-transcript", "tags": "iteration transcript", "modified": "20260424222632000", "preview": "!! 第 133 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 erratum abstract PMID PMCID DOI BOLERO-2 original erratum verbatim\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0131-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424222046000\", \"preview\": \"!! 第 131 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 PMID 22149876 PMC4713958 erratum abstract original corrected sentence\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":10,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0060-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424200117000\", \"preview\": \"!! 第"}, {"title": "Iter-4360dd15-0131-transcript", "tags": "iteration transcript", "modified": "20260424222046000", "preview": "!! 第 131 轮执行轨迹 → call list_recent({"n":8})
【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0133-reflection", "modified": "20260424222636000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424222636000", "tags": "pinned focus"}, {"title": "先锁定权威源再逐字抽句", "modified": "20260424222636000", "tags": "lesson erratum verbatim evidence-chain"}, {"title": "Iter-4360dd15-0133-transcript", "modified": "20260424222632000", "tags": "iteration transcript"}, {"title": "Error-20260425-062224", "modified": "20260424222224000", "tags": "error iteration"}, {"title": "Iter-4360dd15-0131-reflection", "modified": "20260424222053000", "tags": "iteration reflection"}, {"title": "先抓原句边界再谈纠错范围", "modified": "20260424222053000", "tags": "lesson erratum verbatim evidence-chain"}, {"title": "Iter-4360dd15-0131-transcript", "modified": "20260424222046000", "tags": "iteration transcript"}]}
→ call read_note({"title":"NEXT_FOCUS"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission 4360dd15 · Iter-0133）\n\n直接从原文与 erratum 中抽出摘要原句及其修正句，完成 PMID/PMCID/DOI 绑定的逐字对照链。"}
→ call web_search({"limit":5,"query":"PMID 22149876 PMC4713958 BOLERO-2 erratum abstract"})
→ call web_search({"limit":5,"query":"BOLERO-2 erratum 10.1007/s12325-014-0150-8 PMC4713958"})
【tool:web_search】
{"ok": true, "query": "PMID 22149876 PMC4713958 BOLERO-2 erratum abstract", "results": []}
【tool:web_search】
{"ok": true, "query": "BOLERO-2 erratum 10.1007/s12325-014-0150-8 PMC4713958", "results": [{"title": "PDF Erratum to: Everolimus Plus Exemestane in Postmenopausal ... - Springer", "url": "https://link.springer.com/content/pdf/10.1007/s12325-014-0150-8.pdf", "snippet": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A. Yardley • Shinzaburo Noguchi Michael Gnant • Gabriel N. Hortobagyi Bohuslav Melichar • Katarina Petrakova Wentao Feng • Ayelet Cahana • Tetiana Taran"}, {"title": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/", "snippet": "This corrects the article \" Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis \" in volume 30 on page 870."}, {"title": "(PDF) Erratum to: Everolimus Plus Exemestane in ... - ResearchGate", "url": "https://www.researchgate.net/publication/258044358_Erratum_to_Everolimus_Plus_Exemestane_in_Postmenopausal_Patients_with_HR_Breast_Cancer_BOLERO-2_Final_Progression-Free_Survival_Analysis", "snippet": "In the phase III BOLERO-2 trial, exemestane plus everolimus was compared to exemestane plus placebo in patients with HR-positive advanced breast cancer who had recurrence or progression during ..."}, {"title": "Erratum to: Everolimus Plus Exemestane in ... - Semantic Scholar", "url": "h
→ call web_fetch({"max_chars":7000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/"})
→ call web_search({"limit":5,"query":"PMC 22149876 BOLERO-2 final progression-free survival analysis PMC"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Adv Ther . 2014 Sep 11;31:1008–1009. doi: 10.1007/s12325-014-0150-8 Search in PMC Search in PubMed View in NLM Catalog Add to search Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A Yardley De
【tool:web_search】
{"ok": true, "query": "PMC 22149876 BOLERO-2 final progression-free survival analysis PMC", "results": [{"title": "Progression-free or overall survival…revisited in BOLERO-2 - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4080643/", "snippet": "Data presented by Dr. Piccart showed that after progression on study treatment, a somewhat higher fraction of subjects in the control arm received chemotherapy and a slightly higher fraction in the everolimus arm received further endocrine therapy. So how should we consider the results of BOLERO-2 trial?"}, {"title": "Progression-free or overall survival…revisited in BOLERO-2. - Europe PMC", "url": "https://europepmc.org/article/PMC/PMC4080643", "snippet": "Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial."}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal ..."}, {"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://aacrjournals.org/cancerres/article/72/24_Supplement/P6-04-02/576954/Abstract-P6-04-02-Final-progression-free-survival", "snippet": "Interim analyses o
→ call web_search({"limit":8,"query":"\"BOLERO-2 Final Progression-Free Survival Analysis\" PMID"})
→ call web_search({"limit":8,"query":"\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" abstract"})
【tool:web_search】
{"ok": true, "query": "\"BOLERO-2 Final Progression-Free Survival Analysis\" PMID", "results": [{"title": "PDF Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast ...", "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "snippet": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A. Yardley • Shinzaburo Noguchi • Kathleen I. Pritchard Michael Gnant • Gabriel N. Hortobagyi • Mario Campone Bohuslav Melichar • Katarina Petrakova • Francis P. Arena Wentao Feng • Ayelet Cahana • Tetiana Taran • David Lebwohl"}, {"title": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with ...", "url": "https://link.springer.com/article/10.1007/s12325-014-0150-8", "snippet": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Erratum Published: 11 September 2014 Volume 31, pages 1008-1009, (2014) Cite this article Download PDF Save article Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris III ..."}]}
【tool:web_search】
{"ok": true, "query": "\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" abstract", "results": [{"title": "PDF Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast ...", "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "snippet": "ABSTRACT Introduction: positive (HR?) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy . Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III tria [ abstract ]."}, {"title": "Everolimus plus exemestane in postmenopausal patients with HR ...", "url": "https://europepmc.org/article/MED/24158787", "snippet": "Characterization of the overall survival benefit in ENCORE 301, a randomized placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer [ abstract ]."}, {"title": "Everolimus Plus Exemestane in Postmenopausal ... - Semantic Scholar", "url": "https://www.semanticscholar.org/paper/Everolimus-Plus-Exemestane-in-Postmenopausal-with-Yardley-Noguchi/18628012e9bd5552cb865900148821bee522c82c", "snippet": "The addition of everolimus to exemestane markedly prolonged PFS in patients with HR+ advanced BC with disease recurrence/progression following prior NSAIs, and results further support the use ofEverolimus plus exemstane in this patient population. Intro
→ call web_fetch({"max_chars":8000,"url":"https://link.springer.com/article/10.1007/s12325-013-0060-1"})
【tool:web_fetch】
{"ok": true, "url": "https://link.springer.com/article/10.1007/s12325-013-0060-1", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis | Advances in Therapy | Springer Nature Link Skip to main content Advertisement Log in Menu Find a journal Publish with us Track your research Search Saved research Cart Home Advances in Therapy Article Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Original Research Open access Published: 25 October 2013 Volume 30 , pages 870–884, ( 2013 ) Cite this article You have full access to this open access article Download PDF Save article View saved research Advances in Therapy Aims and scope Submit manuscript Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Download PDF Denise A. Yardley 1 , Shinzaburo Noguchi 2 , Kathleen I. Pritchard 3 , Howard A. Burris III 1 , José Baselga 4 , Michael Gnant 5 , Gabriel N. Hortobagyi 6 , Mario Campone 7 , Barbara Pistilli 8 , Martine Piccart 9 , Bohuslav Melichar 10 , Katarina Petrakova 11 , Francis P. Arena 12 , Frans Erdkamp 13 , Wael A. Harb 14 , Wentao Feng 15 , Ayelet Cahana 15 , Tetiana Taran 15 , David Lebwohl 15 & … Hope S. Rugo 16 Show authors 24k Accesses 492 Citations 41 Altmetric 2 Mentions Explore al
→ call web_search({"limit":10,"query":"\"including patients with visceral metastases, patients with recurrence during or within 12 months of completion of adjuvant therapy, and irrespective of age\" BOLERO-2"})
→ call web_search({"limit":10,"query":"\"Final study results with median 18-month follow-up show that median PFS remained significantly longer\" BOLERO-2"})
【tool:web_search】
{"ok": true, "query": "\"including patients with visceral metastases, patients with recurrence during or within 12 months of completion of adjuvant therapy, and irrespective of age\" BOLERO-2", "results": [{"title": "Everolimus Plus Exemestane in Postmenopausal Patients with HR", "url": "https://link.springer.com/article/10.1007/s12325-013-0060-1", "snippet": "Methods BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR + advanced BC with recurrence/progression during or after NSAIs."}]}
【tool:web_search】
{"ok": true, "query": "\"Final study results with median 18-month follow-up show that median PFS remained significantly longer\" BOLERO-2", "results": [{"title": "PDF Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast ...", "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "snippet": "BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR?advanced BC with recurrence/progression during or after S. Noguchi Department of Breast and Endocrine Surgery, Osaka University, Suita, Osaka 565-0871, Japan"}, {"title": "Everolimus Plus Exemestane in Postmenopausal Patients with ... - Paperity", "url": "https://paperity.org/p/36489807/everolimus-plus-exemestane-in-postmenopausal-patients-with-hr-breast-cancer-bolero-2", "snippet": "Methods: BOLERO-2 is a phase 3, double-blind, randomized, international trial (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR? advanced BC with recurrence/progression during or after NSAIs. The primary endpoint was PFS by local investigator review, and was confirmed by independent central radiology review."}, {"title": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast ...", "url": "https://escholarship.org/uc/item/0715f3jd", "snippet": "Methods BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (
→ call web_fetch({"max_chars":12000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Adv Ther . 2014 Sep 11;31:1008–1009. doi: 10.1007/s12325-014-0150-8 Search in PMC Search in PubMed View in NLM Catalog Add to search Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A Yardley De
→ call pubmed_search({"limit":5,"query":"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis"})
【tool:pubmed_search】
{"ok": true, "query": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis", "results": [{"pmid": "24158787", "title": "Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.", "source": "Adv Ther", "pubdate": "2013 Oct", "authors": ["Yardley DA", "Noguchi S", "Pritchard KI", "Burris HA 3rd", "Baselga J", "Gnant M", "Hortobagyi GN", "Campone M"], "url": "https://pubmed.ncbi.nlm.nih.gov/24158787/"}]}
→ call web_search({"limit":10,"query":"PMCID BOLERO-2 final progression-free survival analysis 24158787"})
→ call web_search({"limit":10,"query":"PMC original article 10.1007/s12325-013-0060-1 BOLERO-2 final progression-free survival analysis"})
【tool:web_search】
{"ok": true, "query": "PMCID BOLERO-2 final progression-free survival analysis 24158787", "results": [{"title": "Everolimus plus exemestane in postmenopausal patients with HR ...", "url": "https://europepmc.org/article/MED/24158787", "snippet": "Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer: BOLERO-2 final progression-free survival analysis ."}, {"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://aacrjournals.org/cancerres/article/72/24_Supplement/P6-04-02/576954/Abstract-P6-04-02-Final-progression-free-survival", "snippet": "Interim analyses of the BOLERO-2 trial demonstrated that combining the oral mammalian target of rapamycin (mTOR) inhibitor, everolimus (EVE), with the steroidal aromatase inhibitor, exemestane (EXE), significantly prolonged progression-free survival (PFS) in this patient population. Protocol-specified final PFS analyses are presented."}, {"title": "PDF Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast ...", "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "snippet": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A. Yardley • Shinzaburo Noguchi • Kathleen I. Pritchard Michael Gnant • Gabriel N. Hortobagyi • Mario Campone Bohuslav Melichar • Katarina Petrakova • Francis P. Arena Wentao Feng • Ayelet Cahana • Tetiana Taran • David Lebwoh
【tool:web_search】
{"ok": true, "query": "PMC original article 10.1007/s12325-013-0060-1 BOLERO-2 final progression-free survival analysis", "results": [{"title": "Everolimus Plus Exemestane in Postmenopausal Patients with HR", "url": "https://link.springer.com/article/10.1007/s12325-013-0060-1", "snippet": "The final analysis of the primary endpoint from the BOLERO-2 study demonstrates that EVE+EXE is well tolerated and provides clinically meaningful PFS benefit versus EXE alone in the overall population of patients with HR + advanced BC progressing during/after NSAI therapy, irrespective of age, and among clinically relevant subsets of patients ..."}, {"title": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast ...", "url": "https://escholarship.org/uc/item/0715f3jd", "snippet": "Initial Breast Cancer Trials of OraL EveROlimus-2 ( BOLERO-2 ) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population."}, {"title": "Everolimus plus exemestane in postmenopausal patients with ... - Europe PMC", "url": "https://europepmc.org/article/PMC/PMC3898123", "snippet": "Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer: BOLERO-2 final progression-free survival analysis ."}, {"title": "Everolimus Plus Exemestane in Postmenopausal ... - Semantic Scholar", "url": "https://www.semanticscholar.org/paper/Everolimus-Plus-Exemestane-in-Postmenopausal-
→ call web_fetch({"max_chars":12000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3898123/"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3898123/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Adv Ther . 2013 Oct 25;30(10):870–884. doi: 10.1007/s12325-013-0060-1 Search in PMC Search in PubMed View in NLM Catalog Add to search Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
```